Mostra i principali dati dell'item
Quality of Life and Anxiety in Patients with First Diagnosed Non-Muscle Invasive Bladder Cancer Who Receive Adjuvant Bladder Therapy
dc.creator | Vaioulis A., Bonotis K., Perivoliotis K., Kiouvrekis Y., Gravas S., Tzortzis V., Karatzas A. | en |
dc.date.accessioned | 2023-01-31T10:24:25Z | |
dc.date.available | 2023-01-31T10:24:25Z | |
dc.date.issued | 2021 | |
dc.identifier | 10.3233/BLC-201524 | |
dc.identifier.issn | 23523727 | |
dc.identifier.uri | http://hdl.handle.net/11615/80337 | |
dc.description.abstract | BACKGROUND: Bladder cancer (BC) is one of the most common malignancies (4.5%of all newly diagnosed cases worldwide). Most of the new BC cases are diagnosed as non-muscle invasive BC (NMIBC), needing continuous follow up after primary endoscopic therapy. Adjuvant bladder therapy with chemo- or immuno- agents, apart from the initial diagnosis, the strict surveillance program and the risk of recurrence, may have a major impact on the patients' physical and mental health. OBJECTIVE: We evaluated anxiety and quality of life (QoL) in patients who underwent surgery for NMIBC and followed a bladder instillation programme. METHODS: This is a prospective analysis of patients with histopathologically confirmed NMIBCs. Eligible were all adult patients with a single or multiple NMIBCs who underwent a transurethral tumor resection and followed a therapy with either BCG or Epirubicin instillations. The SF-36 questionnaire Physical and Mental health aspects were used for QoL assessment. Similarly, the STAI-Y was introduced for the state (STAI-Y1) and trait anxiety (STAI-Y2) evaluation. RESULTS: 117 eligible patients were screened, with 108 entering finally the study; 9 patients were excluded due to disease recurrence. 17 patients (15.7%) received Epirubicin (Ta-T1, Low Grade tumors), whereas 91 patients (84.3%) received BCG (T1, High Grade). Regarding SF-36 Physical a 6 months decrease was followed by an improvement at 12 months (p=0.008). Similarly, an increase of the SF-36 Mental health score was identified (p=0.03). In contrast to STAI-Y2 scores (p=0.945), a long-term reduction of the state anxiety was identified (p=0.001). Preoperative SF-36 Physical was inversely correlated with age (p=0.029), while absence of alcohol was associated with lower mental health (p=0.003). Overall, patient characteristics, habits and the administered treatment did not affect the postoperative QoL and anxiety. CONCLUSION: Patient QoL and anxiety improved during follow up. Still, further larger scale studies are required to support our findings. © 2021 - IOS Press. All rights reserved. | en |
dc.language.iso | en | en |
dc.source | Bladder Cancer | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85114457578&doi=10.3233%2fBLC-201524&partnerID=40&md5=1c80f7e3e5453d3b74c8c3bfea8291fb | |
dc.subject | BCG vaccine | en |
dc.subject | epirubicin | en |
dc.subject | adjuvant therapy | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | anxiety | en |
dc.subject | Article | en |
dc.subject | bladder irrigation | en |
dc.subject | cancer surgery | en |
dc.subject | controlled study | en |
dc.subject | Cronbach alpha coefficient | en |
dc.subject | female | en |
dc.subject | follow up | en |
dc.subject | histopathology | en |
dc.subject | human | en |
dc.subject | internal consistency | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | mental health | en |
dc.subject | non muscle invasive bladder cancer | en |
dc.subject | prospective study | en |
dc.subject | quality of life | en |
dc.subject | questionnaire | en |
dc.subject | Short Form 36 | en |
dc.subject | IOS Press BV | en |
dc.title | Quality of Life and Anxiety in Patients with First Diagnosed Non-Muscle Invasive Bladder Cancer Who Receive Adjuvant Bladder Therapy | en |
dc.type | journalArticle | en |
Files in questo item
Files | Dimensione | Formato | Mostra |
---|---|---|---|
Nessun files in questo item. |